Preclinical pharmacology of neuroleptics: Focus on new generation compounds

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 11, 1996, Pages

  Richelson, Elliott ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUPHENAZINE; HALOPERIDOL; HISTAMINE H1 RECEPTOR ANTAGONIST; LOXAPINE; LOXAPINE SUCCINATE; MOLINDONE; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2 ANTAGONIST; SERTINDOLE; THIORIDAZINE; TIOTIXENE;

DRUG ACTIVITY; DRUG INDUCED DISEASE; DRUG RESEARCH; HUMAN; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR BLOCKING; REVIEW; UNITED STATES;

ANTIPSYCHOTIC AGENTS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, DOPAMINE D2; RECEPTORS, HISTAMINE; RECEPTORS, MUSCARINIC; RECEPTORS, SEROTONIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 10544231051     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Driscoll MS, Rothe MJ, Grantkels JM, et al. Delusional parasitosis: a dermatologic, psychiatric, and pharmacologic approach. J Am Acad Dermatol 1993;29:1023-1033
2. i values. J Pharmacol Exp Ther 1989;251:238-246
3. Coffey L. Options for the treatment of negative symptoms of schizophrenia. CNS Drugs 1994;1:107-118
4. Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-26
5. Van Tol HH, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-614
6. Roth BL, Tandra S, Burgess LH, et al. D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (Berl) 1995;120:365-368
7. Glatt CE, Snowman AM, Sibley DR, et al. Clozapine: selective labeling of sites resembling 5HT(6) serotonin receptors may reflect psychoactive profile. Molecular Medicine 1995;1:398-406
8. Bolden C, Cusack B, Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 1992;260:576-580
9. Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration of the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983;3:1607-1619
10. White FJ, Wang RY. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 1983;221: 1054-1057
11. 2 receptors. J Pharmacol Exp Ther 1993;266:1374-1384
12. Creese A, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481-483
13. Seeman P, Lee T, Chau-Wong M, et al. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261:717-719
14. Richelson E, Nelson A. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 1984;103: 197-204
15. Moore NA, Calligaro DO, Wong DT, et al. The pharmacology of olanzapine and other new antipsychotic agents. Current Opinion in Investigative Drugs 1993;2:281-293
16. Hyttel J, Arnt J, Costall B, et al. Pharmacological profile of the atypical neuroleptic sertindole. Clin Neuropharmacol 1992;15:267a-268a
17. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-544
18. Skarsfeldt T. Pharmacology of sertindole, a novel atypical neuroleptic. New Generation of Antipsychotic Drugs: Novel Mechanisms of Action 1993;4:62-66
19. Wander TJ, Nelson A, Okazaki H, et al. Antagonism by neuroleptics of serotonin 5-HT1A and 5-HT2 receptors of normal human brain in vitro. Eur J Pharmacol 1987;143:279-282
20. Dewey SL, Smith GS, Logan J, et al. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 1995;15:821-829
21. Davis KL, Kahn RS, Ko G, et al. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991;148:1474-1486
22. Devaud LL, Hollingsworth EB, Cooper BR. Alterations in extracellular and tissue levels of biogenic amines in rat brain induced by the serotonin(2) receptor antagonist, ritanserin. J Neurochem 1992;59:1459-1466
23. Duinkerke SJ, Botter PA, Jansen AAI, et al. Ritanserin, a selective 5-HT(2/1c) antagonist, and negative symptoms in schizophrenia: a placebo-controlled double-blind trial. Br J Psychiatry 1993;163:451-455
24. Ohuoha DC, Hyde TM, Kleinman JE. The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system. Psychopharmacology (Berl) 1993;112(suppl 1):S5-S15
25. Lucas JJ, Hen R. New players in the 5-HT receptor field: genes and knockouts. Trends Pharmacol Sci 1995;16:246-252
26. Sokoloff P, Schwartz JC. Novel dopamine receptors half a decade later. Trends Pharmacol Sci 1995;16:270-275
27. Van Tol HHM, Wu CM, Guan HC, et al. Multiple dopamine-D4 receptor variants in the human population. Nature 1992; 358:149-152
28. Sommer SS, Lind TJ, Heston LL, et al. Dopamine-D(4) receptor variants in unrelated schizophrenic cases and controls. Am J Med Genet 1993;48: 90-93
29. Petronis A, Macciardi F, Athanassiades A, et al. Association study between the dopamine D4 receptor gene and schizophrenia. Am J Med Genet 1995;60:452-455
30. Seeman P, Guan HC, Van Tol HHM. Dopamine D4 receptors elevated in schizophrenia. Nature 1993;365:441-445
31. 125]epidepride. Eur J Pharmacol 1995;286:R3-R5
32. Miller RJ, Hiley CR. Anti-muscarinic properties of neuroleptics and drug-induced parkinsonism. Nature 1974;248:596-597
33. Snyder S, Greenberg D, Yamamura HI. Antischizophrenic drugs and brain cholinergic receptors: affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry 1974;31:58-61
34. Kubo T, Fukuda K, Mikami A, et al. Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature 1986;323:411-416
35. Bonner TI, Buckley NJ, Young AC, et al. Identification of a family of muscarinic acetylcholine receptor genes. Science 1987;237:527-532
36. Bolden C, Cusack B, Richelson E. Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-K1 cells. Eur J Pharmacol 1991;192:205-206
37. Flynn DD, Ferraridileo G, Mash DC, et al. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem 1995;64:1888-1891
38. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl) 1993;112:285-292
39. Boyson SJ, McGonigle P, Luthin GR, et al. Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum. J Pharmacol Exp Ther 1988;244:987-993
40. Fritze J, Elliger T. Pirenzepine for clozapine-induced hypersalivation [letter]. Lancet 1995;346:1034
41. Zorn SH, Jones SB, Ward KM, et al. Clozapine is a potent and selective muscarinic M(4) receptor agonist. Eur J Pharmacol 1994;269:R1-R2
42. Zeng XP, Le F, Scarisbrick I, et al. Muscarinic m4 receptor agonism by atypical but not typical antipsychotics. Society for Neuroscience Abstracts 1995;21:1707
43. Skarsfeldt T. Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 1995;281:289-294
44. Mereu G, Lilliu V, Vargiu P, et al. Failure of chronic haloperidol to induce depolarization inactivation of dopamine neurons in unanesthetized rats. Eur J Pharmacol 1994;264:449-453
45. Mereu G, Lilliu V, Vargiu P, et al. Depolarization inactivation of dopamine neurons: an artifact? J Neurosci 1995;15:1144-1149
46. Buvat J, Lemaire A, Buvat-Herbaut M, et al. Hyperprolactinemia and sexual function in men. Horm Res 1985;22:196-203
47. Schwartz JC, Arrang JM, Garbarg M, et al. Histamine. In: Kupfer D, Bloom F, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:397-405
48. Gardos G, Cole JO. Weight reduction in schizophrenics by molindone. Am J Psychiatry 1977;134:302-304
49. Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995;21:463-472
50. 2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics? [letter] Journal of Psychopharmacology 1995;9:155